SHANDONG XINHUA (00719) Secures Approval for Subsidiary’s Saxagliptin and Metformin Hydrochloride Sustained-release Tablets

Bulletin Express03-04 17:14

Shandong Xinhua Pharmaceutical Company Limited (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, recently received a Drug Registration Certificate from the National Medical Products Administration for Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) and (Ⅲ). According to the announcement dated 4 March 2026, the product is approved for improving blood sugar control in adult patients with type 2 diabetes, under diet and exercise therapy.

The tablets are included in the “National Drug Catalogue for Basic Medical Insurance, Work Related-Injury Insurance, and Maternity Insurance (2025)” as a Category B product. Official data indicate that Saxagliptin and Metformin Hydrochloride Sustained-release Tablets registered total sales of 419.00 million yuan in 2024 across China’s public medical institutions. The company expects this approval to broaden its hypoglycemic preparation portfolio and strengthen its overall market competitiveness while acknowledging that sales remain subject to policy changes and market fluctuations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196795109?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 17:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196795109","market":"us","top_or_hot":-1,"title":"SHANDONG XINHUA (00719) Secures Approval for Subsidiary’s Saxagliptin and Metformin Hydrochloride Sustained-release Tablets","media":"Bulletin Express","content":"<p>Shandong Xinhua Pharmaceutical Company Limited (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, recently received a Drug Registration Certificate from the National Medical Products Administration for Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) and (Ⅲ). According to the announcement dated 4 March 2026, the product is approved for improving blood sugar control in adult patients with type 2 diabetes, under diet and exercise therapy.</p>\n<p>The tablets are included in the “National Drug Catalogue for Basic Medical Insurance, Work Related-Injury Insurance, and Maternity Insurance (2025)” as a Category B product. Official data indicate that Saxagliptin and Metformin Hydrochloride Sustained-release Tablets registered total sales of 419.00 million yuan in 2024 across China’s public medical institutions. The company expects this approval to broaden its hypoglycemic preparation portfolio and strengthen its overall market competitiveness while acknowledging that sales remain subject to policy changes and market fluctuations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SHANDONG XINHUA (00719) Secures Approval for Subsidiary’s Saxagliptin and Metformin Hydrochloride Sustained-release Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSHANDONG XINHUA (00719) Secures Approval for Subsidiary’s Saxagliptin and Metformin Hydrochloride Sustained-release Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-04 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shandong Xinhua Pharmaceutical Company Limited (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, recently received a Drug Registration Certificate from the National Medical Products Administration for Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) and (Ⅲ). According to the announcement dated 4 March 2026, the product is approved for improving blood sugar control in adult patients with type 2 diabetes, under diet and exercise therapy.</p>\n<p>The tablets are included in the “National Drug Catalogue for Basic Medical Insurance, Work Related-Injury Insurance, and Maternity Insurance (2025)” as a Category B product. Official data indicate that Saxagliptin and Metformin Hydrochloride Sustained-release Tablets registered total sales of 419.00 million yuan in 2024 across China’s public medical institutions. The company expects this approval to broaden its hypoglycemic preparation portfolio and strengthen its overall market competitiveness while acknowledging that sales remain subject to policy changes and market fluctuations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00719","symbol_name":"山东新华制药股份","start_time":0,"source_url":"","article_id":"1196795109","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196795109","pubTimestamp":1772615649,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shandong Xinhua Pharmaceutical Company Limited (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, recently received a Drug Registration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00719":"山东新华制药股份"},"translate_title":"山东新华(00719)子公司沙格列汀盐酸二甲双胍缓释片获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"Shandong Xinhua Pharmaceutical Company Limited (00719) announced that its wholly-owned subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, recently received a Drug Registration Certificate from the National Medical Products Administration for Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ) and (Ⅲ). According to the announcement dated 4 March 2026, the product is approved for improving blood sugar control in adult patients with type 2 diabetes, under diet and exercise therapy.\nThe tablets are included in the “National Drug Catalogue for Basic Medical Insurance, Work Related-Injury Insurance, and Maternity Insurance (2025)” as a Category B product. Official data indicate that Saxagliptin and Metformin Hydrochloride Sustained-release Tablets registered total sales of 419.00 million yuan in 2024 across China’s public medical institutions. The company expects this approval to broaden its hypoglycemic preparation portfolio and strengthen its overall market competitiveness while acknowledging that sales remain subject to policy changes and market fluctuations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196795109","isCrawlerRequest":true}